

**Statement-III**

*State-wise No. of Suspected Dental Fluorosis cases (cumulative)  
in school children*

Sl. No.	State	Suspected Dental Fluorosis cases in school children (cumulative)**
1.	Andhra Pradesh	2976
2.	Telangana	9777
3.	Assam	811
4.	Bihar	969
5.	Chhattisgarh	153
6.	Gujarat	1910
7.	Haryana	2669
8.	Jharkhand	852
9.	Jammu and Kashmir	NA
10.	Karnataka	434230
11.	Kerala	8782
12.	Madhya Pradesh	3690
13.	Maharashtra	2511
14.	Odisha	NA
15.	Punjab	7007
16.	Rajasthan	87146
17.	Tamil Nadu	15643
18.	Uttar Pradesh	590
19.	West Bengal	12129
TOTAL		5,91,845

\*\*\* As per data provided by States in State Monitoring Reports.

**Healthcare infrastructure in the country**

296. DR. K. V. P. RAMACHANDRA RAO: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that the healthcare infrastructure in India is inadequate when compared to Global Standards, if so, the details thereof;

(b) whether it is also a fact that India is lagging behind several nations in global ranking in the healthcare sector under several indicators, if so, the details thereof; and

(c) whether Government has specific strategy to improve the situation in the healthcare sector?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI FAGGAN SINGH KULASTE): (a) and (b) A study titled “Measuring the health-related Sustainable Development Goals in 188 Countries: a baseline analysis from the Global Burden of Disease Study 2015” published recently in “The Lancet” placed India in 143rd position. The study provides an analysis of 33 health-related Sustainable Development Goal (SDG) indicators.

(c) Public Health and hospitals is a State subject. The Government of India has recently approved the National Health Policy (NHP) which provides detailed framework and policy thrust areas to improve healthcare sector in a time bound manner.

#### **Displaying of generic names on medicine packets**

297. SHRI K. K. RAGESH: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) the steps taken by Government to ensure display of generic names prominently along with trade name or branded name of allopathic medicines; and

(b) whether any time-frame has been kept for pharmaceutical companies for such compulsory display of generic names, if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI FAGGAN SINGH KULASTE): (a) Rule 96 of the Drugs and Cosmetics Rules, 1945 provides that name of the drug shall be printed or written in a more conspicuous manner than the trade name, if any, which shall be shown immediately after or under the proper name.

Further, Ministry of Health and Family Welfare has published a draft notification for public comments *vide* GSR 302 (E) dated 30.03.2017 for amendment of Rule, 96 to provide that the proper name of the drugs shall be printed in a conspicuous manner which shall be in the same font but at level two font size larger than the brand name or the trade name, if any.

(b) The pharmaceuticals companies are required to comply with all the provisions, including Rule 96, of the Drugs and Cosmetics Rules, 1945. However no time-frame has been provided in the said GSR notification dated 30.03.2017